Dr. Jay M. Bhatt, M.D.
ENT (Otolaryngology) (Pediatric Otolaryngology Physician)
At a glance
- In the NPI registry since
- 2012
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Otolaryngology Physician primary
CA license A126898 (first issued 2013; current) · CO license DR0058490 (first issued 2017; expired) -
Otolaryngology Physician
CA license A126898 (first issued 2013; current) · CO license DR0058490 (first issued 2017; expired) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $69.17 in total to this clinician.
| Inspire Medical Systems, Inc. | $41.36 |
|---|---|
| Boston Scientific Corporation | $27.81 |
| Food and Beverage | $69.17 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $30,522 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Paratek Pharmaceuticals, Inc. · Recruiting · NCT06850805 - OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
Paratek Pharmaceuticals, Inc. · Completed · NCT03747458
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.